{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 5.5.2.2 Storage and Disposition of Blinded Investigational Product(s)', 'Subsection Rovalpituzumab Tesirine/Placebo', 'Add: new last sentence', 'Specific storage conditions for reconstituted and diluted rovalpituzumab tesirine/placebo', 'will be provided in a separate document outside of this protocol.', 'Section 5.5.2.3 Preparation/Reconstitution of Dosage Form(s)', 'Fourth sentence previously read:', 'The rovalpituzumab tesirine drug product is dosed based on body weight.', 'Has been changed to read:', 'The rovalpituzumab tesirine drug product is dosed based on actual body weight.', 'Section 5.5.2.3 Preparation/Reconstitution of Dosage Form(s)', 'Add: new tenth sentence', 'Specific dose preparation and documentation details will be provided to the site pharmacy', 'in a separate document.', 'Section 5.5.4.1 Dosing', 'First paragraph', 'Add: new last sentence', 'In cases of weight gain due to fluid retention, dosing should be based on most recent pre-', 'fluid retention actual weight.', 'Table 5. Dose Reductions and Discontinuation for Unacceptable Toxicities', 'Toxicity \"Grade 4 LFTs or Grade 3 LFTs with concomitant Bilirubin Grade 2 or', 'higher\" previously read:', 'Grade 4 LFTs or Grade 3 LFTs with concomitant Bilirubin Grade 2 or higher', '175']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Grade 4 LFTs or Grade 3 LFTs with concomitant Bilirubin Grade 2 or higherb', 'Table 5. Dose Reductions and Discontinuation for Unacceptable Toxicities', 'Add: new toxicity \"Grade 2 pneumonitis\" and \"Grade > 3 pneumonitis\"', 'Grade 2 pneumonitis', 'Reduce dose to 0.1 mg/kg', 'Discontinue Rova-T', 'Grade > 3 pneumonitis', 'Discontinue Rova-T', 'N/A', 'Table 5. Dose Reductions and Discontinuation for Unacceptable Toxicities', 'Add: new footnote \"b.\"', 'b. If potential DILI is suspected please follow guidelines of Section 6.1.8.3.', 'Section 5.5.5.2 Blinding of Data for Independent Data Monitoring Committee', '(IDMC)', 'Last sentence previously read:', 'Final PFS data with interim OS data will be analyzed and reviewed by the IDMC for', 'recommendation.', 'Has been changed to read:', 'For the futility analysis, OS, other efficacy and safety data will be analyzed and reviewed', 'by the IDMC for recommendation.', 'Section 5.5.7 Drug Accountability', 'Fourth paragraph', 'Add: new last sentence', 'Rova-T is classified as a Dangerous Good/Hazardous Material according to US', 'Department of Transportation (DOT) and International Air Transport Association (IATA).', '176']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Dangerous Goods/Hazardous Materials must be packaged and shipped according to', 'applicable regulations.', 'Section 6.1.1.3 Adverse Events Expected Due to SCLC or Progression of SCLC', 'Last paragraph previously read:', '\"Disease progression\" should not be captured when reporting AEs or SAEs, even if fatal,', 'as disease progression is an efficacy endpoint for the trial. Rather, symptoms of disease', 'progression should be reported as AEs or SAEs as appropriate.', 'Has been changed to read:', 'Although exempted from expedited reporting to Health Authorities and Institutional', 'Review Boards (IRBs) as individual cases, these SAEs must be reported to the Sponsor', 'within 24 hours of the site being made aware of the SAE.', 'AEs or SAEs should not be reported as \"Disease progression,\" even if fatal, as PD is an', 'efficacy endpoint for the study. Rather, report the specific disease (clinical) manifestation', \"of the progression (eg, 'malignant pleural effusion, 'spinal bone metastases,'\", '\\'lymphadenopathy,\\' \\'brain metastases\\') or if not possible, report \"malignant neoplasm', 'progression\" as the AE or SAE as appropriate.', 'Section 6.1.4 Deaths', 'Second paragraph previously read:', 'Deaths that occur during the protocol specified AE reporting period (Section 6.1.6) that', 'are more likely related to disease progression will therefore be considered as an expected', 'AE and will not be subject to expedited reporting. These events should be captured as', 'disease progression and recorded on the AE eCRF. After the AE reporting period, deaths', 'attributed to progression of disease under study should not be recorded on the AE eCRF.', '177']\n\n###\n\n", "completion": "END"}